Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU

Background: Leishmaniasis (LI) is a vector-borne illness caused by a protozoan of the genus Leishmania. Data on the features of LI in patients with inflammatory bowel disease (IBD) are scarce. Aim: To describe the characteristics of patients with IBD who present with leishmaniasis, infection outcome...

Descripción completa

Detalles Bibliográficos
Autores: Madero-Velázquez, L, Minguez, A, Mayorga, L, Ramirez, J, Moreno, N, Amorós, C, Nieto, M, Mena, R, Benitez, J, Gimeno-Pitarch, L, Maroto, N, Suria, C, Rodriguez-Moranta, F, Ordas,, Ruiz, L, Garcia-Brenes, MA, Martin-Cardona, A, de Celix, CR, Cárdenas, K, Ginard, D, Medina, L, Pédrero, N, Plaza, R, Salmoral, R, Martinez-Pérez, T, Algara,, Merino, E, Zabana, Y, Gutiérrez, A, Young Grp GETECCU
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p11110
Acceso en línea:https://isabial.portalinvestigacion.com/publicaciones11110
https://doi.org/10.1002/ueg2.12740
Access Level:acceso abierto
Palabra clave:biologics
Crohn's disease
IBD
immunosuppression
opportunistic infection
parasitic
ulcerative colitis
Descripción
Sumario:Background: Leishmaniasis (LI) is a vector-borne illness caused by a protozoan of the genus Leishmania. Data on the features of LI in patients with inflammatory bowel disease (IBD) are scarce. Aim: To describe the characteristics of patients with IBD who present with leishmaniasis, infection outcomes and the risk factors associated with developing visceral leishmaniasis (VL). Methods: An observational retrospective study performed in 26 hospitals in Spain, including all adult patients with IBD who developed Leishmaniasis from 2012 to 2022. Results: A total of 73 patients were included [mean age 48 years; 65% male; 68% Crohn's disease]. Sixty patients (82.2%) presented localized cutaneous Leishmaniasis (CL), 2 (2.7%) diffuse CL, 3 (4.1%) mucocutaneous Leishmaniasis (MCL) and 8 (11%) VL. All patients were under biologicals (69 [94.5%]) or immunosuppressants (IMM) (4 [5.5%]) at Leishmaniasis diagnosis. AntiTNF was used in 97%, while 2 patients (3%) were receiving ustekinumab. Leishmaniasis resolution was achieved by 48% and 96% of the patients after 1 and 12 months, respectively. Biological withdrawal after Leishmaniasis diagnosis was not statistically related to increased rates of infection resolution among patients with localized CL. Age was the only risk factor associated with VL (OR 1.2, 95%CI 1.04-1.39; p = 0.012). Conclusions: Leishmaniasis in patients with IBD doesn't seem to follow a complicated clinical course, even in those with localized CL who do not discontinue biological therapy after infection diagnosis. Age might be a risk factor for developing VL. This infection should be considered for immunosuppressed patients with IBD and suggestive symptoms dwelling or travelling to endemic areas.

Similares en LA Referencia